Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned End Date changed from 1 Jul 2021 to 31 Aug 2022.
- 26 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Aug 2018.